Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025

Group 1 - Genmab A/S reported worldwide net trade sales of DARZALEX (daratumumab) totaling USD 14,351 million in 2025, with USD 8,266 million from the U.S. and USD 6,085 million from the rest of the world [1][5] - Genmab receives royalties on the worldwide net sales of DARZALEX, which includes both intravenous and subcutaneous products, under an exclusive license agreement with Johnson & Johnson [1][5] - The company has a strong late-stage clinical pipeline and is focused on delivering transformative antibody-based medicines to patients [2] Group 2 - Established in 1999, Genmab is headquartered in Copenhagen, Denmark, and has a global presence across North America, Europe, and Asia Pacific [3] - Genmab has been dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines for over 25 years [2]